Diplomat Pharmacy (DPLO) Tops Q1 EPS by 1c; Boosts FY15 Outlook

Diplomat Pharmacy (NYSE: DPLO) reported Q1 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $625 million versus the consensus estimate of $629.6 million.

Diplomat Pharmacy sees FY2015 EPS of $0.48-$0.51, versus prior guidance of $0.47-$0.50 and the consensus of $0.47. Diplomat Pharmacy sees FY2015 revenue of $2.9-3.1 billion, versus prior guidance of $2.8-3.1 billion and the consensus of $3.01 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• National Healthcare (NHC) Tops Q2 EPS by 174c
• Starz Entertainment Corp. (STRZ) Reports Q2 Loss of $11.27